Literature DB >> 10498865

Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice.

Y Yao1, E D Slosberg, L Wang, H Hibshoosh, Y J Zhang, W Q Xing, R M Santella, I B Weinstein.   

Abstract

Cdc25 phosphatases activate cyclin-dependent kinases (Cdks) by dephosphorylating critical phospho-tyrosine and phospho-threonine residues on these proteins. Several types of studies indicate that Cdc25s can enhance cell proliferation and oncogenesis. Furthermore, overexpression of Cdc25A and/or B have been detected in several types of primary human cancers, including breast cancers. To further assess the oncogenic capacity of Cdc25B in vivo, we have generated transgenic mice that overexpress Cdc25B in the mammary epithelium, driven by the MMTV - LTR promoter. Although these mice are grossly normal for up to 18 months, the ectopic expression of Cdc25B in their mammary glands increases the susceptibility of these mice to induction of mammary tumors by the carcinogen 9,10-dimethyl-1, 2-benzanthracene (DMBA).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10498865     DOI: 10.1038/sj.onc.1202908

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  Absence of apparent phenotype in mice lacking Cdc25C protein phosphatase.

Authors:  M S Chen; J Hurov; L S White; T Woodford-Thomas; H Piwnica-Worms
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

Review 2.  Signal transduction in transgenic mouse models of human breast cancer--implications for human breast cancer.

Authors:  Richard Marcotte; William J Muller
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-07-24       Impact factor: 2.673

3.  Heterozygous disruption of the TATA-binding protein gene in DT40 cells causes reduced cdc25B phosphatase expression and delayed mitosis.

Authors:  M Um; J Yamauchi; S Kato; J L Manley
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

4.  Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells.

Authors:  R Reeves; D D Edberg; Y Li
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

5.  Increased susceptibility to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in transgenic mice overexpressing c-myc and epidermal growth factor in alveolar type II cells.

Authors:  A Ehrhardt; T Bartels; R Klocke; D Paul; R Halter
Journal:  J Cancer Res Clin Oncol       Date:  2003-02-19       Impact factor: 4.553

Review 6.  Cell cycle proteins as promising targets in cancer therapy.

Authors:  Tobias Otto; Piotr Sicinski
Journal:  Nat Rev Cancer       Date:  2017-01-27       Impact factor: 60.716

Review 7.  In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets.

Authors:  Hiroaki Kiyokawa; Dipankar Ray
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

8.  Variations in intracellular levels of TATA binding protein can affect specific genes by different mechanisms.

Authors:  Stephanie D Bush; Patricia Richard; James L Manley
Journal:  Mol Cell Biol       Date:  2007-10-22       Impact factor: 4.272

9.  LGH00031, a novel ortho-quinonoid inhibitor of cell division cycle 25B, inhibits human cancer cells via ROS generation.

Authors:  Yu-bo Zhou; Xu Feng; Li-na Wang; Jun-qing Du; Yue-yang Zhou; Hai-ping Yu; Yi Zang; Jing-ya Li; Jia Li
Journal:  Acta Pharmacol Sin       Date:  2009-09       Impact factor: 6.150

Review 10.  The role and target potential of protein tyrosine phosphatases in cancer.

Authors:  Taolin Yi; Daniel Lindner
Journal:  Curr Oncol Rep       Date:  2008-03       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.